|
1
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Workman P: Altered states: selectively
drugging the Hsp90 cancer chaperone. Trends Mol Med. 10:47–51.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kobayashi N, Toyooka S, Soh J, et al: The
anti-proliferative effect of heat shock protein 90 inhibitor,
17-DMAG, on non-small-cell lung cancers being resistant to EGFR
tyrosine kinase inhibitor. Lung Cancer. 75:161–166. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jackman DM, Yeap BY, Sequist LV, et al:
Exon 19 deletion mutations of epidermal growth factor receptor are
associated with prolonged survival in non-small cell lung cancer
patients treated with gefitinib or erlotinib. Clin Cancer Res.
12:3908–3914. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riely GJ, Pao W, Pham D, et al: Clinical
course of patients with non-small cell lung cancer and epidermal
growth factor receptor exon 19 and exon 21 mutations treated with
gefitinib or erlotinib. Clin Cancer Res. 12:839–844. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giaccone G: Clinical impact of novel
treatment strategies. Oncogene. 21:6970–6981. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grabley S and Thiericke R: Bioactive
agents from natural sources: trends in discovery and application.
Adv Biochem Eng Biotechnol. 64:101–154. 1999.PubMed/NCBI
|
|
8
|
Wang Y, Zhang YJ, Gao WY and Yan LL:
Anti-tumor constituents from Paris polyphylla var. yunnanensis.
Zhongguo Zhong Yao Za Zhi. 32:1425–1428. 2007.(In Chinese).
|
|
9
|
Sun J, Liu BR, Hu WJ, et al: In vitro
anticancer activity of aqueous extracts and ethanol extracts of
fifteen traditional Chinese medicines on human digestive tumor cell
lines. Phytother Res. 21:1102–1104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee MS, Yuet-Wa JC, Kong SK, et al:
Effects of polyphyllin D, a steroidal saponin in Paris polyphylla,
in growth inhibition of human breast cancer cells and in xenograft.
Cancer Biol Ther. 4:1248–1254. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheung JY, Ong RC, Suen YK, et al:
Polyphyllin D is a potent apoptosis inducer in drug-resistant HepG2
cells. Cancer Lett. 217:203–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Siu FM, Ma DL, Cheung YW, et al: Proteomic
and transcriptomic study on the action of a cytotoxic saponin
(Polyphyllin D): induction of endoplasmic reticulum stress and
mitochondria-mediated apoptotic pathways. Proteomics. 8:3105–3117.
2008. View Article : Google Scholar
|
|
13
|
Jiang H, Su D and Ma SL: The effect of
Chonglou Saponin I on proliferation and apoptosis in lung
adenocarcinoma cell line PC9. J Chinese Oncol. 18:166–169.
2012.
|
|
14
|
Hua YH, Ma SL, Fu ZF, et al: Effect of
Polyphyllin I on radiosensitivity in nasopharyngeal carcinoma cell
line CNE-2 in vitro. Chinese Archives of Traditional Chinese
Medicine. 29:1387–1390. 2011.(In Chinese).
|
|
15
|
Xiao M, Dai X, He X, et al: Paris saponin
I induces G2/M cell cycle arrest and apoptosis in human
gastric carcinoma SGC7901 cells. J Huazhong Univ Sci Technol Med
Sci. 31:768–772. 2011.PubMed/NCBI
|
|
16
|
Xiao X, Bai P, Bui Nguyen TM, et al: The
antitumoral effect of Paris Saponin I associated with the induction
of apoptosis through the mitochondrial pathway. Mol Cancer Ther.
8:1179–1188. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yan LL, Zhang YJ, Gao WY, et al: In vitro
and in vivo anticancer activity of steroid saponins of Paris
polyphylla var. yunnanensis. Exp Oncol. 31:27–32. 2009.PubMed/NCBI
|
|
18
|
Ji Y, Ma SL, Zhang YP, et al: Combined
treatment with TNF-alpha/gefitinib alleviates the resistance to
gefitinib in PC-9 cells. Anticancer Drugs. 20:832–837. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hengartner MO: The biochemistry of
apoptosis. Nature. 407:770–776. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shroff EH, Snyder C and Chandel NS: Bcl-2
family members regulate anoxia-induced cell death. Antioxid Redox
Signal. 9:1405–1409. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Reed JC, Miyashita T, Takayama S, et al:
BCL-2 family proteins: regulators of cell death involved in the
pathogenesis of cancer and resistance to therapy. J Cell Biochem.
60:23–32. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sedlak TW, Oltvai ZN, Yang E, et al:
Multiple Bcl-2 family members demonstrate selective dimerizations
with Bax. Proc Natl Acad Sci USA. 92:7834–7838. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zha L, Qiao T, Yuan S, et al: Enhancement
of radiosensitivity by CpG-oligodeoxyribonucleotide-7909 in human
non-small cell lung cancer A549 cells. Cancer Biother Radiopharm.
25:165–170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma S, Tang J, Feng J, et al: Induction of
p21 by p65 in p53 null cells treated with Doxorubicin. Biochim
Biophys Acta. 1783:935–940. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tang JJ, Shen C and Lu YJ: Requirement for
pre-existing of p21 to prevent doxorubicin-induced apoptosis
through inhibition of caspase-3 activation. Mol Cell Biochem.
291:139–144. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao GH, Beeser A, Chernoff J and Testa
JR: p21-activated kinase links Rac/Cdc42 signaling to merlin. J
Biol Chem. 277:883–886. 2002. View Article : Google Scholar : PubMed/NCBI
|
